Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00187551 · ClinicalTrials.gov registry record · Phase 4
Pilot Study Evaluating Interruption of Enfuvirtide (Fuzeon, T20) in Patients With Enfuvirtide Resistance
A Phase 4 study of HIV Infections, sponsored by University of California, San Francisco.
- Completed
- Registry status
- Phase 4
- Development phase
- 25
- Enrollment target
- 1
- Study location
NCT00187551: Completed Phase 4 study of HIV Infections, sponsored by University of California, San Francisco.
NCT00187551 is a Phase 4 study of HIV Infections that has completed, run by University of California, San Francisco. The registered enrollment target is 25 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00187551, a Phase 4 study of HIV Infections, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this study is to examine whether enfuvirtide (T20, Fuzeon) has continued anti-HIV activity in patients experiencing an incomplete virologic response to an enfuvirtide-based regimen.
Conditions Studied
Interventions
- OTHER Interruption of enfuvirtide
- OTHER enfuvirtide interrupton
Study Locations (1)
California
- San Francisco General Hospital - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2000-05 |
| Est. Completion | 2005-11 |
| Phase | Phase 4 |
What the finished NCT00187551 record still lists
NCT00187551 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (94% lower).
The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 2 interventions - of which Interruption of enfuvirtide is the first listed.
NCT00187551 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT00187551 about?
NCT00187551 is a clinical study titled "Pilot Study Evaluating Interruption of Enfuvirtide (Fuzeon, T20) in Patients With Enfuvirtide Resistance". The goal of this study is to examine whether enfuvirtide (T20, Fuzeon) has continued anti-HIV activity in patients experiencing an incomplete virologic response to an enfuvirtide-based regimen.
What is the current status of trial NCT00187551?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 25 participants. The study started on 2000-05. Estimated completion is 2005-11.
What conditions does trial NCT00187551 study?
This clinical trial studies the following conditions: HIV Infections.
What interventions are being tested in trial NCT00187551?
The interventions under investigation include: Interruption of enfuvirtide (OTHER), enfuvirtide interrupton (OTHER).
Who is sponsoring clinical trial NCT00187551?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00187551 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00187551's enrollment target sits among peer trials
25 461st of 542 higher than 74 of 542 other HIV Infections trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other HIV Infections trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Accelerated ART Initiation for PWHIV Who Are Out of Care
RECRUITING · Phase 4
-
Vaccine Immunity and Inflammation in the Aging Person Living With HIV
RECRUITING · Phase 4
-
PrEP Intervention for People Who Inject Substances and Use Methamphetamine
RECRUITING · Phase 4
-
Boosted Atazanavir and Truvada Given Once-Daily - BATON Study
COMPLETED · Phase 4
-
"The Once A Day Protease Inhibitor Regimens"
COMPLETED · Phase 4
-
Buprenorphine and Integrated HIV Care
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia